No Evidence of Disease Clinical Trial
Official title:
A Comparison of Acute and Long-term Toxicities in Bone Marrow Donors With and Without G-CSF Treatment Prior to Harvest: A Companion Study to ASCT0631
This randomized clinical trial is studying the side effects of collection of bone marrow from donors treated with or without filgrastim. Giving colony-stimulating factors, such as filgrastim (G-CSF), to donors helps the stem cells move from the bone marrow to the blood so they can be collected and stored.
PRIMARY OBJECTIVES:
I. To evaluate short- and long-term toxicities in bone marrow donors treated with vs without
filgrastim before harvest.
II. To compare 10-year mortality and cancer in donors treated with vs without filgrastim.
SECONDARY OBJECTIVES:
I. To correlate the incidence of acute and chronic graft-vs-host disease in the marrow
recipients enrolled on COG-ASCT0631 with four parameters assessed in the bone marrow
harvests: absolute T-cell numbers, Th1 vs Th2 profile of T-cells, dendritic cell populations,
and T-regulatory cell content.
OUTLINE: Donors are randomized to 1 of 2 treatment arms.
ARM I (unstimulated harvest): Donors undergo conventional (i.e., unstimulated) bone marrow
harvest on day 0.
ARM II (stimulated harvest): Donors receive filgrastim subcutaneously on days -4 through 0.
Donors then undergo bone marrow harvest on day 0.
After completion of study treatment, donors are followed up at 1, 6, and 12 months and then
annually for up to 10 years.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01230346 -
Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer
|
N/A | |
Recruiting |
NCT03156309 -
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
|
Phase 1 | |
Active, not recruiting |
NCT02780401 -
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
|
Phase 1 | |
Completed |
NCT02099136 -
Celecoxib in Preventing the Damaging Effects of Sunburn in Healthy Volunteers
|
Phase 2 | |
Completed |
NCT03725449 -
Internet-based Intervention for Skin Self-Examination in Participants With Increased Risk for Melanoma
|
N/A | |
Completed |
NCT01497431 -
Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants
|
Phase 1 | |
Withdrawn |
NCT03120390 -
Physical Activity in Reducing Metabolic Dysregulation (MetD) in Obese Latina Breast Cancer Survivors
|
N/A | |
Completed |
NCT02090933 -
Celecoxib in Decreasing the Damaging Effects of Sunburn in Healthy Volunteers
|
Phase 2 | |
Terminated |
NCT02735512 -
MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer
|
||
Completed |
NCT02961790 -
Oxybutynin Chloride in Managing Hot Flashes
|
Phase 3 | |
Completed |
NCT02288416 -
Video-Based Intervention in Reducing Anxiety in Patients Undergoing Lung Cancer Screening
|
N/A | |
Completed |
NCT01698294 -
Biomarkers in Post-Menopausal Women Receiving Flaxseed
|
N/A | |
Completed |
NCT00896974 -
Study of 9cUAB30 in Healthy Participants
|
Phase 1 | |
Terminated |
NCT03284346 -
Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors
|
N/A |